We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Expanded Range of Quality Control Sera Ensures Reliable Results

By LabMedica International staff writers
Posted on 10 Aug 2009
An expanded range of quality control sera ensures reliable results for the clinical laboratory, as well as being timesaving and economic.

Called Acusera, the new range includes controls for blood gas, coagulation, drugs of abuse, heart (liquid cardiac), liquid clinical chemistry, maternal screening, tumor markers, and urinalysis.

Acusera, produced by Randox (Crumlin, UK), is supplied with accurate instrument and method-specific values. Bottles, caps, and packaging are color-coded to help distinguish different analyte levels and minimize errors. Quality-control materials can be used alongside Randox reagents or as third-party controls from an independent manufacturer. Randox also offers quality-control materials tailored to customers' specifications.

Randox is an international diagnostics company, which develops, manufactures, and markets clinical diagnostic products worldwide. Core products include biochip array technology; clinical chemistry analyzers and reagents; quality controls; and recombinant proteins and antibodies.

Related Links:
Randox




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Gastrointestinal Panel
Xpert® GI Panel
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT

Latest Clinical Chem. News

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment
10 Aug 2009  |   Clinical Chem.

Multimodal Platform to Combine Blood and Imaging Biomarkers for Lung Nodule Assessment
10 Aug 2009  |   Clinical Chem.

Study Links Saliva-Based Epigenetic Signals to OCD Treatment Outcomes
10 Aug 2009  |   Clinical Chem.